{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T00:31:20Z","timestamp":1716078680617},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bpgastro.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.bpg.2013.06.017","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T06:12:14Z","timestamp":1380607934000},"page":"597-618","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Liver abnormalities in the immunosuppressed"],"prefix":"10.1016","volume":"27","author":[{"given":"Michelle C.M.","family":"Cheung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bpg.2013.06.017_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"1","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.bpg.2013.06.017_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrclinonc.2012.1","article-title":"Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer","volume":"9","author":"Torres","year":"2012","journal-title":"Rev Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2013.06.017_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/liv.12055","article-title":"Management of HBV in immunocompromised patients","volume":"33","author":"Pol","year":"2013","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.bpg.2013.06.017_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcv.2007.11.017","article-title":"The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting","volume":"41","author":"Barclay","year":"2008","journal-title":"J Clin Virol"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib5","first-page":"18","article-title":"The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma \u2013 a review","volume":"2","author":"Marcucci","year":"2012","journal-title":"Am J Blood Res"},{"issue":"5","key":"10.1016\/j.bpg.2013.06.017_bib6","first-page":"396","article-title":"Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis","volume":"1","author":"Xiao","year":"2008","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/hep.1840130122","article-title":"Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis","volume":"13","author":"Davies","year":"1991","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0016-5085(98)70380-4","article-title":"Treatment of fibrosing cholestatic hepatitis with lamivudine","volume":"115","author":"Chan","year":"1998","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2013.06.017_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2013.06.017_bib10","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis an examination of FDA safety reports","volume":"2","author":"Evens","year":"2011","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2013.06.017_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1478-3231.2010.02396.x","article-title":"The difficulties of managing severe hepatitis B virus reactivation","volume":"31","author":"Roche","year":"2011","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2013.06.017_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1440-1746.2012.07280.x","article-title":"Hepatitis B virus reactivation associated with anti-neoplastic therapy","volume":"28","author":"Yeo","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2013.06.017_bib15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2036.2009.04158.x","article-title":"Screening for hepatitis B in chemotherapy patients: survey of current oncology practices","volume":"31","author":"Tran","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.bpg.2013.06.017_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-148-7-200804010-00008","article-title":"Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy","volume":"148","author":"Loomba","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bpg.2013.06.017_bib17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrrheum.2012.63","article-title":"Management of rheumatic disease with comorbid HBV or HCV infection","volume":"8","author":"Vassllopoulos","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bpg.2013.06.017_bib18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1634\/theoncologist.2010-0106","article-title":"Hepatitis B reactivation and rituximab in the oncology practic","volume":"15","author":"Villadolid","year":"2010","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.bpg.2013.06.017_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1634\/theoncologist.2010-0182","article-title":"An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7 year institutional experience of hepatitis screening","volume":"16","author":"Leung","year":"2011","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.bpg.2013.06.017_bib20","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/annonc\/mdh430","article-title":"Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy","volume":"15","author":"Yoe","year":"2004","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bpg.2013.06.017_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2013.06.017_bib22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"Paptheodoridis","year":"2012","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2013.06.017_bib24","first-page":"482","article-title":"Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature","volume":"80","author":"Kawai","year":"2011","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.bpg.2013.06.017_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol Int"},{"issue":"57","key":"10.1016\/j.bpg.2013.06.017_bib26","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"19","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"19","key":"10.1016\/j.bpg.2013.06.017_bib27","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","article-title":"ASCO Provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases","volume":"28","author":"Artz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bpg.2013.06.017_bib28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","article-title":"NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas","volume":"8","author":"Zelenetz","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"26","key":"10.1016\/j.bpg.2013.06.017_bib29","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2011.40.7510","article-title":"Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis","volume":"30","author":"Zurawska","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bpg.2013.06.017_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7326\/0003-4819-156-10-201205150-00013","article-title":"Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable","volume":"156","author":"Lok","year":"2012","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.bpg.2013.06.017_bib31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","article-title":"Hepatitis B virus reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies","volume":"65","author":"Calabrese","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/00365548.2011.611819","article-title":"Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodkin's lymphoma patients treated with immunochemotherapy","volume":"44","author":"Nosotti","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.bpg.2013.06.017_bib33","first-page":"1331","article-title":"Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia?","volume":"35","author":"Libra","year":"2010","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(02)00773-8","article-title":"Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue","volume":"3","author":"Vento","year":"2002","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.bpg.2013.06.017_bib35","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2010-06-289231","article-title":"Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis","volume":"116","author":"Ennishi","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib36","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","article-title":"Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients","volume":"57","author":"Mahale","year":"2012","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2013.06.017_bib37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0168-8278(96)80136-X","article-title":"Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic stud","volume":"24","author":"Sheen","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2013.06.017_bib38","first-page":"945950","article-title":"Rituximab-based treatment, HCV replication, and hepatic flares","author":"Sagnelli","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"8994","key":"10.1016\/j.bpg.2013.06.017_bib39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0140-6736(96)90212-3","article-title":"Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus","volume":"347","author":"Vento","year":"1996","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bpg.2013.06.017_bib40","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10067-012-1988-2","article-title":"Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs","volume":"31","author":"Tan","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3109\/s10165-011-0458-z","article-title":"Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and\/or nonbiological disease-modifying antirheumatic drugs","volume":"21","author":"Mori","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.bpg.2013.06.017_bib42","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.gcb.2009.03.021","article-title":"Inflammatory bowel disease and hepatitis B and C","volume":"33","author":"Chevaux","year":"2009","journal-title":"Gastroenterol Clin BIol"},{"issue":"3","key":"10.1016\/j.bpg.2013.06.017_bib43","first-page":"363","article-title":"Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis","volume":"18","author":"Mok","year":"2000","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.bpg.2013.06.017_bib44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/art.1780360307","article-title":"Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis","volume":"36","author":"Walker","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrrheum.2012.63","article-title":"Management of rheumatic disease with comorbid HBV or HCV infection","volume":"8","author":"Vassilopoulous","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.bpg.2013.06.017_bib46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/0003-4819-112-5-381","article-title":"Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy","volume":"112","author":"Flowers","year":"1990","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib47","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rhuem"},{"issue":"5","key":"10.1016\/j.bpg.2013.06.017_bib48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.bpg.2013.06.017_bib49","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","article-title":"Prophylaxis and treatment of hepatitis B in immunocompromised patients","volume":"39","author":"Marzano","year":"2007","journal-title":"Dig Liver Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.bpg.2013.06.017_bib50","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/S1590-8658(07)60018-8","article-title":"Cyclosporin in steroid-resistant autoimmune hepatitis and HCV-related liver diseases","volume":"39","author":"Fagiuoli","year":"2007","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.bpg.2013.06.017_bib51","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14656560902731951","article-title":"Treatment strategies for a patient with rheumatoid arthritis and hepatitis C","volume":"10","author":"Giannitii","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"10.1016\/j.bpg.2013.06.017_bib52","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3748\/wjg.v19.i9.1342","article-title":"Hepatitis B and inflammatory bowel disease:role of antiviral prophylaxis","volume":"19","author":"Lopez-Serrano","year":"2013","journal-title":"World J Gatroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2013.06.017_bib53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/14712598.2012.646986","article-title":"Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management","volume":"12","author":"Vigano","year":"2012","journal-title":"Expert Opin Bio Ther"},{"issue":"10","key":"10.1016\/j.bpg.2013.06.017_bib54","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"Perez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.bpg.2013.06.017_bib56","first-page":"1944","article-title":"Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection","volume":"35","author":"Ferri","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bpg.2013.06.017_bib57","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C","volume":"62","author":"Peterson","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib58","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1572-0241.2007.01131.x","article-title":"Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease","volume":"102","author":"Abdelmalek","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2013.06.017_bib59","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2013.06.017_bib61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"3","author":"Rahier","year":"2009","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.bpg.2013.06.017_bib62","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2011.01.003","article-title":"Viral hepatitis in solid organ transplantation other than liver","volume":"55","author":"Vallet-Pichard","year":"2011","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2013.06.017_bib63","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00007890-200102150-00008","article-title":"Results on preemptive or prophylactive treatment of lamivudine in HBsAg+ renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence","volume":"71","author":"Han","year":"2001","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.bpg.2013.06.017_bib64","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00007890-200208270-00001","article-title":"Management of chronic viral hepatitis before and after renal transplantation","volume":"74","author":"Gane","year":"2002","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib65","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis B and C on kidney transplantation outcome","volume":"29","author":"Mathurin","year":"1999","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2013.06.017_bib66","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kasiske","year":"2009","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib67","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.TP.0000116448.97841.6D","article-title":"Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials","volume":"77","author":"Fabrizi","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2013.06.017_bib68","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e318273fec4","article-title":"Hepatitis C virus and nonliver solid organ transplantation","volume":"95","author":"Carbone","year":"2013","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.bpg.2013.06.017_bib69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL clinical practice guidelines: management of hepatitis C","volume":"55","author":"Craxi","year":"2011","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2013.06.017_bib70","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients","volume":"10","author":"Kucirka","year":"2010","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.bpg.2013.06.017_bib71","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2010.03280.x","article-title":"Long-term experience with kidney transplant from hepatitis C-positive donors into hepatitis C-positive recipients","volume":"10","author":"Morales","year":"2010","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.bpg.2013.06.017_bib72","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jhep.2009.11.009","article-title":"Liver grafts from anti-hepatitis B core positive donors: a systematic review","volume":"52","author":"Cholangitas","year":"2010","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.bpg.2013.06.017_bib73","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/00007890-199911270-00010","article-title":"The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group","volume":"68","author":"Locasciulli","year":"1999","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.bpg.2013.06.017_bib74","first-page":"980","article-title":"Prevalence, incidence and clinical outcome of hepatitis B virus and hepatitis C virus hepatitis in patients undergoing allogeneic hematopoietic stem cell transplantation between 2001 and 2004","volume":"91","author":"Francisci","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bpg.2013.06.017_bib75","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bmt.1703826","article-title":"Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)\/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation","volume":"31","author":"Locasciulli","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bpg.2013.06.017_bib76","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/hep.23533","article-title":"Hepatobiliary complications of hematopoietic cell 40 years on","volume":"51","author":"McDonald","year":"2010","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bpg.2013.06.017_bib77","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1182\/blood.V93.10.3259.410k13_3259_3266","article-title":"Cirrhosis of the liver in long-term marrow transplant survivors","volume":"93","author":"Strasser","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bpg.2013.06.017_bib78","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/bmt.2011.238","article-title":"Long-term follow-up of HCV-infected hematopoieti SCT patients and effects of antiviral therapy","volume":"47","author":"Ljungman","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib79","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.bbmt.2009.12.533","article-title":"Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation","volume":"16","author":"Giaccone","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bpg.2013.06.017_bib80","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/bmt.2012.5","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation","volume":"47","author":"Majhail","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bpg.2013.06.017_bib81","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/jmv.20705","article-title":"Lamivudine prophylaxis and treatment of hepatitis B virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab","volume":"78","author":"Moses","year":"2006","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1399-3062.2011.00659.x","article-title":"Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy","volume":"14","author":"Milazzo","year":"2012","journal-title":"Transplant Infect Dis"},{"issue":"2","key":"10.1016\/j.bpg.2013.06.017_bib83","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.bmt.1702453","article-title":"Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study","volume":"26","author":"Kim","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"10.1016\/j.bpg.2013.06.017_bib84","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3748\/wjg.v18.i16.1851","article-title":"Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation","volume":"18","author":"Tuncer","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib85","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.bpg.2013.06.017_bib86","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.blre.2012.05.001","article-title":"Thrombotic complications associated with stem cell transplantation","volume":"26","author":"Nadir","year":"2012","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.bpg.2013.06.017_bib87","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohot study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.bpg.2013.06.017_bib88","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bbmt.2005.06.008","article-title":"Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver","volume":"11","author":"Duarte","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bpg.2013.06.017_bib89","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib90","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2559.2007.02679.x","article-title":"Histopathology of graft versus host disease of the liver","volume":"50","author":"Quaglia","year":"2007","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib91","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jhep.2005.11.004","article-title":"Epidemiology of viral hepatitis and HIV co-infection","volume":"44","author":"ALter","year":"2006","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2013.06.017_bib92","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/lt.22329","article-title":"Liver transplantation in human immunodeficiency virus-positive patients","volume":"17","author":"Joshi","year":"2011","journal-title":"Liver Transplant"},{"issue":"10","key":"10.1016\/j.bpg.2013.06.017_bib93","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/cid\/cis694","article-title":"Hepatitis C virus infections in the Swiss HIV COhort Study: a rapidly evolving epidemic","volume":"55","author":"Wandeler","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gutjnl-2012-302062","article-title":"HIV and viral hepatitis coinfections: advances and challenges","volume":"61","author":"Lacombe","year":"2012","journal-title":"Gut"},{"issue":"Suppl. 3","key":"10.1016\/j.bpg.2013.06.017_bib95","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1086\/533414","article-title":"Management of hepatic complications in HIV-infected persons","volume":"197","author":"Sulkowski","year":"2008","journal-title":"JID"},{"issue":"9244","key":"10.1016\/j.bpg.2013.06.017_bib96","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","article-title":"Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study","volume":"356","author":"Greub","year":"2000","journal-title":"Lancet"},{"issue":"9772","key":"10.1016\/j.bpg.2013.06.017_bib97","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(10)62001-6","article-title":"Increasing burden of liver disease in patients with HIV infection","volume":"377","author":"Joshi","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bpg.2013.06.017_bib98","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.52.7.1035","article-title":"Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients","volume":"52","author":"Mohsen","year":"2003","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bpg.2013.06.017_bib99","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/COH.0b013e32834b55c7","article-title":"Assessment of liver disease (noninvasive methods)","volume":"6","author":"Mehta","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"10.1016\/j.bpg.2013.06.017_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2009.00781.x","article-title":"British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010","volume":"11","author":"Brook","year":"2010","journal-title":"HIV Med"},{"issue":"8","key":"10.1016\/j.bpg.2013.06.017_bib101","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1478-3231.2012.02796.x","article-title":"HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians","volume":"32","author":"Ingilz","year":"2012","journal-title":"Liver Int"}],"container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691813001303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691813001303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T09:34:02Z","timestamp":1716024842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691813001303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S1521691813001303"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2013.06.017","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver abnormalities in the immunosuppressed","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2013.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}